서린바이오

038070KOSDAQ기타 전문 도매업

40.0 / 100

Reference Date: 2026-04-13

Financial Score12.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 6.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Sorin Bio operates as a 'Global Total Solutions Provider in Life Science & Healthcare', focusing on bio industry solutions, sanitation/sterilization services, AI-based bio analysis, and healthcare. Approximately 97.2% of its revenue comes from bio industry total solutions, which includes supplying raw materials, reagents, and equipment essential for biopharmaceutical development to research institutions and pharmaceutical companies.

Number of Employees

110people

Average Salary

60.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

98.82Industry Average 15.630.0Point

6.3x industry avg (risky)

PBR

0.66Industry Average 0.632.5Point

Higher than industry avg (caution)

ROE

0.66Industry Average 2.091.0Point

Well below industry avg

Debt Ratio

1.25Industry Average 7.878.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼6.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼44.6% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.5% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 6,230Won52-week high 8,21552-week low 6,050

1-month return2.0Point

1m -6.17% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-02
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-02
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-02
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26